BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
BioAge Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.99+0.15 (+3.10%)
Close on Oct 19, 2026
- Market cap
- $223.75M
- P/E (TTM)
- –
- Dividend yield
- –
BioAge Labs statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Market Cap | $229.03M | $166.30M |
| Enterprise Value | -$89.72M | $88.19M |
| PS Ratio | 22.12 | 3.65 |
| PB Ratio | 0.61 | 2.03 |
| P/TBV Ratio | 0.61 | 2.29 |
Enterprise value
| Measure | BioAge Labs | Industry median |
|---|---|---|
| EV / Sales | -8.66 | 2.51 |
Income (trailing twelve months)
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Revenue | $10.36M | $58.34M |
| Operating Income | -$106.27M | -$21.40M |
| Net Income | -$94.46M | -$22.46M |
| EBITDA | -$106.27M | -$16.91M |
| EPS (Diluted) | -$2.38 | -$0.83 |
Margins
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Operating Margin | -1026.3% | -44.0% |
| Profit Margin | -912.3% | -40.2% |
| EBITDA Margin | -1026.3% | -30.2% |
| FCF Margin | -850.7% | -9.27% |
Returns
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Return on Equity (ROE) | -28.2% | -53.2% |
| Return on Assets (ROA) | -26.3% | -40.9% |
| Return on Invested Capital (ROIC) | -283.4% | -32.4% |
| Return on Capital Employed (ROCE) | -28.1% | -38.1% |
Growth
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 168.1% | 5.96% |
Balance sheet
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $318.75M | $61.43M |
| Total Debt | $0 | $118.52M |
| Net Cash (Debt) | $318.75M | $15.35M |
| Net Cash Per Share | $6.94 | $0.66 |
| Equity (Book Value) | $374.91M | $49.09M |
| Book Value Per Share | $8.17 | $1.37 |
| Tangible Book Value | $374.91M | $23.52M |
| Working Capital | $311.10M | $76.81M |
Financial position
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Current Ratio | 17.19 | 3.34 |
| Quick Ratio | 16.62 | 2.44 |
| Debt / Equity | 0.00 | 0.52 |
| Interest Coverage | -378.19 | -6.26 |
Cash flow (trailing twelve months)
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Operating Cash Flow | -$87.60M | -$12.35M |
| Capital Expenditures | -$488.00K | -$1.08M |
| Free Cash Flow | -$88.09M | -$20.22M |
| FCF Per Share | -$1.92 | -$0.42 |
Efficiency
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.39 |
| Revenue Per Employee | $167.02K | $404.87K |
| Profits Per Employee | -$1.52M | -$703.34K |
| Employee Count | 62 | 74 |
Dividends and yields
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Earnings Yield | -41.2% | -23.3% |
| FCF Yield | -38.5% | -8.72% |
Shares
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Shares Outstanding | 45,896,900 | 58,127,000 |
| Shares Change (QoQ) | 3.13% | 0.54% |
| Float | 35,832,400 | 49,136,700 |
| Shares Held by Insiders | 21.9% | 11.6% |
| Shares Held by Institutions | 82.2% | 59.4% |
Scores
| Measure | BioAge Labs | Industry median |
|---|---|---|
| Altman Z-Score | 4.98 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from BioAge Labs's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.